Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from January 2021.
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from January 2021.
5. A Drug Indication Is Pulled From the Market: Now What?
Drug approvals are seemingly happening faster than ever before, with many therapies being granted accelerated approvals based on promising interim results from clinical trials. But what happens when the data in later confirmatory trials is not as good, and treatments may be pulled from the market? Learn more in this piece.
4. Secondline Maintenance PARP Inhibition in Ovarian Cancer: Pros and Cons
While PARP inhibitors in the second-line maintenance setting have allowed some patients with recurrent ovarian cancer to derive prolonged progression-free survival, while being spared chemotherapy-related toxicities, choosing between the 3 approved PARP inhibitors remains a significant challenge, as this piece examines.
3. Managers Can Promote or Improve Nurse Loneliness
Even though nurses may be around people all day, they may still feel lonely, which could lead to job dissatisfaction, compromised patient care, and a high turnover rate among nurses, according to recent research published in the Journal of Nursing Management.
2. Step Count May Boost QOL in Patients Receiving SM-88
Mean daily step count during the first 2 weeks of treatment with SM-88 was found to correlate with overall self-reported quality of life in patients with metastatic pancreatic cancer, according to trial results presented during the 2021 Gastrointestinal Cancers Symposium.
1. Precision Medicine: Where We've Been, Where We're Going
Targeted therapy and immunotherapy have drastically shifted the cancer landscape in recent years, but there is still more to accomplish in the way of precision medicine, according to the American Cancer Society’s “Blueprint for cancer research: critical gaps and opportunities.”
Thanks for reading!
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
Published: January 27th 2025 | Updated: January 28th 2025T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer
January 26th 2025While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.